tickerreport.com
Positivewww.tickerreport.com ·
Sutro Biopharma Nasdaqstro Hits New 52 Week High Following Analyst Upgrade
OverweightDiseasesObesityHealth Nutrition And Populati…
Topic context
This topic has been covered 383549 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe news is a stock price reaction to analyst upgrades, not a fundamental commercial mechanism. No product/commodity price, supply chain, or margin impact is reported. The event is company-specific and does not indicate sector-wide changes.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Sutro Biopharma (NASDAQ:STRO) shares hit a new 52-week high of $39.74 on May 7, 2026.
- Truist Financial upgraded the stock to a strong-buy rating.
- Lifesci Capital and Citizens Jmp also upgraded ratings and price targets.
- Consensus rating is 'Moderate Buy' with an average target price of $40.78.
- Sutro is a clinical-stage biopharma company focused on oncology and immunology, market cap ~$660M.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
nbclosangeles.com
Spacex Confirms Plans for IPO
manilatimes.net